MGI(SH:688114) Zhi Tong Cai Jing·2026-02-27 09:31Core Viewpoint - The company, BGI Genomics, reported significant improvements in its financial performance for the fiscal year 2025, with a notable reduction in losses and a focus on enhancing operational efficiency through various strategic initiatives [1][2]. Financial Performance - For the fiscal year 2025, the company achieved a revenue of 2.78 billion yuan, with a narrowed net loss of 237 million yuan, representing a 60.57% year-on-year reduction in losses [1]. - The non-recurring net loss was 378 million yuan, which is a 42.11% year-on-year improvement [1]. - Operating expenses (excluding financial costs) decreased by approximately 19% year-on-year, indicating improved operational efficiency [1]. Product Development and Market Position - The company launched several key products in 2025, including the T1+ sequencer, which received high industry recognition and saw rapid growth in installation volume [1]. - The T7+ sequencer achieved cost reduction and quality improvement, while the E25 sequencer received NMPA certification and significantly increased sales, expanding into European and Latin American markets [1]. - BGI Genomics has achieved a market share of approximately 70% in public tenders in China for 2025, reflecting its leading position in the industry [1]. Strategic Acquisitions and Technological Advancements - The company announced plans to acquire cutting-edge platforms in spatial genomics and nanopore sequencing, positioning itself as a unique player with a comprehensive product matrix in the life sciences sector [2]. - The CycloneSEQ nanopore sequencing technology is competitive with international leaders, while the Stereo-seq spatial genomics technology outperforms similar products from 10X Genomics [2]. Global Business Strategy and Financial Outlook - BGI Genomics is optimizing its global business layout and upgrading its business model, including the planned sale of its subsidiary Complete Genomics, Inc. for approximately 50 million USD [3]. - This transaction will enhance the company's financial performance, reduce annual losses significantly, and solidify long-term revenue streams [3]. - The company aims to leverage the growing "AI + healthcare" market, benefiting from its advanced technologies and positioning itself for rapid profitability [3].